Decoy Therapeutics Inc.
DCOYDecoy Therapeutics Inc. in brief
Decoy Therapeutics Inc. is a listed company in the Biotechnology industry, based in Houston, Texas, USA. Its market value was $2 M on 23 October 2026, which makes it the 27,622nd largest listed company in the world and the 4,483rd largest in the USA on this site. Its shares trade under the symbol DCOY (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Decoy Therapeutics Inc.
We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through our proprietary IMP3ACT™ platform. Our IMP3ACT™ platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning and artificial intelligence tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. Peptide conjugates are emerging as a major therapeutic drug modality, with the potential to transform multiple therapeutic areas. Utilizing our novel IMP3ACT platform that increases the drug development speed and reduce the complexity of variant synthesis, we aim to build a robust portfolio of novel peptide conjugate therapeutics, initially focusing on infectious diseases and oncology, with the goal of becoming a fully integrated biopharmaceutical company at the forefront of this field. Through this approach, we intend to revolutionize the design, development, and commercialization of peptide conjugate therapeutics. We have no products approved for commercial sales and have not generated any revenue from product sales.
From the company's annual report filed with the US SEC: read the report
Decoy Therapeutics Inc. timeline
- 2014
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2015
- 🔔Initial public offering as Flex Pharma, Inc.Final prospectus filed with the SEC on 29 January 2015; shares registered for exchange trading on 23 January 2015.
- 2019
- ✎Renamed Salarius Pharmaceuticals, Inc.Formerly Flex Pharma, Inc..
- 2020
- 💰Record revenue of $5 millionFY2020, the highest of the 4 years on record.
- 2026
- ✎Renamed Decoy Therapeutics Inc.Formerly Salarius Pharmaceuticals, Inc..
Events of Decoy Therapeutics Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,389 (Oct 2026) · #4,485 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.4×
- Free cash flow yield
- -219.9%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -212.6%
- Liabilities / assets
- 46.7%
- Revenue growth
- -64.8%
- R&D / revenue
- 464.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-13M | $-13M | — |
| Dec 2024 | — | — | $-6M | $-6M | — |
| Dec 2023 | — | — | $-13M | $-13M | — |
| Dec 2022 | — | — | $-32M | $-32M | — |
| Dec 2021 | $2M | -64.8% | $-13M | $-13M | -694.0% |
| Dec 2020 | $5M | +50.7% | $-8M | $-7M | -140.5% |
| Dec 2019 | $3M | +77.9% | $-8M | $-7M | -200.0% |
| Dec 2018 | $2M | — | $-2M | $-2M | -85.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | $1M | $-5M | $-129.10 | — |
| Dec 2024 | $-5M | $0M | $-5M | $-69.54 | — |
| Dec 2023 | $-13M | — | — | $-30.74 | — |
| Dec 2022 | $-18M | — | — | $-14.88 | — |
| Dec 2021 | $-10M | $0M | $-10M | $-7.72 | — |
| Dec 2020 | $-10M | $0M | $-10M | $-0.50 | — |
| Dec 2019 | $-12M | $0M | $-12M | $-2.12 | — |
| Dec 2018 | $4M | $0M | $4M | $-1.16 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 7, 2026S-1IPO registration
- Sep 23, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- Sep 15, 20268-KCurrent reportShareholder vote
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 4, 2026DEF 14AProxy statement
- Jul 15, 20268-KCurrent reportShareholder vote
- Jul 10, 2026S-1IPO registration
- Jun 29, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- Jun 15, 2026S-1IPO registration
- Jun 4, 2026DEF 14AProxy statement
- May 19, 20268-KCurrent reportOther events
Official filings of Decoy Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-13 M
- Net income
- $-13 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $11 M
- Total liabilities
- $5 M
- Total equity
- $6 M
As of December-2025
Top 6 institutional investors in Decoy Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Commonwealth Equity Services, LLC | 32,000 | New | 1.34% | $0 M | Nov 2, 2026 |
| 2 | UBS Group AG | 4,525 | +4,500 (+18000.00%) | 0.19% | $0 M | Nov 10, 2026 |
| 3 | Vanguard Capital Management LLC | 4,034 | 0 (0.00%) | 0.17% | $0 M | Nov 13, 2026 |
| 4 | Tower Research Capital LLC (TRC) | 3,735 | +3,479 (+1358.98%) | 0.16% | $0 M | Nov 16, 2026 |
| 5 | SBI Securities Co., Ltd. | 111 | New | 0.00% | $0 M | Oct 22, 2026 |
| 6 | Jpmorgan Chase & Co | 80 | New | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Decoy Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 5,156 | $0 M | 0.22% | <0.01% | −83% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 4,034 | $0 M | 0.17% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 477 | $0 M | 0.02% | <0.01% | −85% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Decoy Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Mark J. RosenblumChief Financial Officer | Grant or award | +9,682 | — | — | 11,363 | Form 4 |
| filed | Tess BurlesonDirector | Grant or award | +2,000 | — | — | 2,002 | Form 4 |
| filed | Peter Klaus MarschelChief Business Officer | Grant or award | +3,900 | — | — | 3,900 | Form 4 |
| filed | Barbara Louise HibnerChief Scientific Officer | Grant or award | +4,216 | — | — | 4,216 | Form 4 |
| filed | Patricia G. GauthierDirector | Grant or award | +2,000 | — | — | 2,000 | Form 4 |
| filed | Frederick Pierce IIChief Executive Officer | Grant or award | +33,455 | — | — | 34,844 | Form 4 |
| filed | Paul LammersDirector | Grant or award | +2,000 | — | — | 2,001 | Form 4 |
| filed | Arnold C. HanishDirector | Grant or award | +3,000 | — | — | 3,418 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Decoy Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-14.99 reverse split ; 1-for-8 reverse split ; 1-for-25 reverse split ; 1-for-4.28 reverse split
Trading halts
- 2026-09-22 16:51 UTC, code LUDP, resumed 16:56 UTC
- 2026-06-29 13:37 UTC, code LUDP, resumed 13:42 UTC
- 2026-06-29 13:31 UTC, code LUDP, resumed 13:36 UTC
- 2026-06-09 16:01 UTC, code LUDP, resumed 16:06 UTC
- 2026-06-09 15:53 UTC, code LUDP, resumed 15:58 UTC
Fails to deliver
- : 729 shares at $1.03
- : 5,103 shares at $1.07
- : 91 shares at $1.17
- : 343 shares at $1.17
- : 1,947 shares at $1.52
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Decoy Therapeutics Inc. scorecard#
Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 23, 2026.
Valuation1 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.4×Price to book 0.4× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-129.10 vs -69.54Diluted EPS -129.10 in fiscal 2025 against -69.54 the year before (report's currency).
- ✗Net income higher than five years earlier-$13 M-$13 M in fiscal 2025 against -$7 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$13 MNet income -$13 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-338.4%-338.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.1×Current ratio 2.13 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year21.2%Diluted shares up 21.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Decoy Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | 0−100%— | 1.8−64.8%100% | 5.2+51.0%100% | 3.5+77.6%100% | 2.0r0.8+53.1%100% | 1.3+26.1%100% | 1.0—100% | |
| Cost of revenue | — | — | — | — | — | — | — | 0.4−15.0%22.1% | 0.5−23.6%39.7% | 0.7—65.6% | |
| Research and development | 0.4−52.2%— | 0.8−89.3%— | 7.2−54.7%— | 16+85.3%— | 8.5+23.6%465% | 6.9+72.0%132% | 4.0+212%116% | 1.3r12−92.4%66.0% | 17−16.6%1333% | 20—2016% | |
| General and administrative | 3.7−24.9%— | 5.0−13.2%— | 5.7−19.9%— | 7.1+16.9%— | 6.1−0.0%332% | 6.1−20.8%117% | 7.7+228%223% | 2.3r11−87.3%120% | 19−6.8%1452% | 20—1965% | |
| Operating expenses | 13+120%— | 5.7−55.5%— | 13−59.5%— | 32+117%— | 15+12.5%796% | 13+11.0%249% | 12+223%339% | 3.6r23−89.9%186% | 36−12.0%2825% | 41—4047% | |
| Operating income | −13—— | −5.7—— | −13—— | −32—— | −13—−696% | −7.8—−149% | −8.3—−239% | −1.7r−22—−86.3% | −35—−2725% | −40—−3947% | |
| Income tax | 0—— | — | — | — | — | — | 0—0.0% | — | — | — | |
| Income from continuing operations | — | — | — | — | — | −7.4—−140% | −6.9r−6.9—−200% | −1.7—−85.6% | — | — | |
| Income from discontinued operations | — | — | — | — | — | — | 0.0—0.1% | 0—0.0% | — | — | |
| Net income attributable to shareholders | −13—— | −5.6—— | −13—— | −32—— | −13—−694% | −7.4—−140% | −6.9—−200% | −1.7r−22—−85.6% | −34—−2702% | −39—−3908% | |
| Earnings per share, basic | -129.10—— | -69.54r-5.79—— | -30.74r-3.84—— | -14.88—— | -7.72r-0.31—— | -0.50—— | -2.12—— | -1.16r-1.22—— | -1.99—— | -2.43—— | |
| Earnings per share, diluted | -129.10—— | -69.54r-5.79—— | -30.74r-3.84—— | -14.88—— | -7.72r-0.31—— | -0.50—— | -2.12—— | -1.16r-1.22—— | -1.99—— | -2.43—— | |
| Shares, weighted average (basic) | 0.1+20.9%— | 0.1r1.0−80.4%— | 0.4r3.3−80.8%— | 2.1+28.4%— | 1.7r41−89.4%— | 16—— | — | — | — | — | |
| Shares, weighted average (diluted) | 0.1+20.9%— | 0.1r1.0−80.4%— | 0.4r3.3−80.8%— | 2.1+28.4%— | 1.7r41−89.4%— | 16+377%— | 3.3+112%— | 1.5r18−91.1%— | 17+6.3%— | 16—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 11+340%96.9% | 2.4−58.7%80.5% | 5.9−51.3%89.6% | 12−58.6%82.6% | 29+163%71.5% | 11+197%44.6% | 3.7+15.8%26.9% | 3.2r9.8−83.2%48.8% | 19−14.4%54.8% | 22—35.5% | |
| Short-term investments | — | — | — | — | — | — | — | 0−100%0.0% | 14−63.5%40.4% | 39—61.2% | |
| Receivables | — | — | — | — | 1.6−59.0%3.9% | 3.9r3.9—15.6% | 0−100%0.0% | 0.0−4.3%0.2% | 0.0−14.7%0.0% | 0.0—0.0% | |
| Inventory | — | — | — | — | — | — | — | 0.2−56.7%2.8% | 0.4−4.9%1.2% | 0.5—0.7% | |
| Other current assets | 0.3+530%2.5% | 0.0−71.1%1.4% | 0.2−9.7%2.3% | 0.2−3.1%1.1% | 0.2+25.6%0.4% | 0.1+1.3%0.6% | 0.1+511%1.0% | 0.0r0.2−97.1%0.3% | 0.8−16.1%2.2% | 0.9—1.5% | |
| Current assets | 11+268%99.4% | 3.0−54.2%98.8% | 6.5−55.1%99.0% | 15−51.9%99.1% | 30+90.9%73.9% | 16+236%63.4% | 4.7−26.4%33.8% | 6.4r10−81.5%96.5% | 35−44.7%98.7% | 62—98.8% | |
| Property, plant and equipment | 0.0—0.4% | 0—0.0% | — | — | 0.0−65.2%0.0% | 0.0−9.5%0.1% | 0.0−33.3%0.2% | 0.0r0.1−88.7%0.6% | 0.3−40.5%0.9% | 0.6—0.9% | |
| Goodwill | — | — | — | 0−100%0.0% | 8.90.0%21.7% | 8.90.0%35.6% | 8.9—63.8% | 0—0.0% | — | — | |
| Total assets | 11+266%100% | 3.0−54.1%100% | 6.6−55.0%100% | 15−64.1%100% | 41+63.8%100% | 25+79.4%100% | 14+110%100% | 6.6r10−81.1%100% | 35−44.6%100% | 63—100% | |
| Accounts payable | 0.9+0.4%8.5% | 0.9+55.4%31.0% | 0.6−78.9%9.2% | 2.9+85.2%19.5% | 1.5−16.8%3.8% | 1.9+3.5%7.4% | 1.8+372%12.9% | 0.4r0.3−81.1%5.7% | 2.0+68.1%5.7% | 1.2—1.9% | |
| Current liabilities | 5.2+242%46.7% | 1.5—50.0% | — | — | — | — | — | 1.1−81.1%16.7% | 5.8+50.4%16.7% | 3.9—6.2% | |
| Total liabilities | 5.2+242%46.7% | 1.5+16.3%50.0% | 1.3−69.5%19.7% | 4.3+102%29.1% | 2.1−23.9%5.2% | 2.8−16.3%11.1% | 3.3−58.0%23.8% | 7.9r1.1+33.9%119% | 5.9+51.0%16.8% | 3.9—6.2% | |
| Retained earnings | −94—−854% | −82—−2710% | −76—−1159% | −64—−436% | −32—−78.8% | −19—−77.9% | −12—−86.9% | −5.1r−133—−77.7% | −111—−317% | −77—−121% | |
| Shareholders' equity | 5.9+290%53.3% | 1.5−71.4%50.0% | 5.3−49.1%80.3% | 10−73.2%70.9% | 39+74.7%94.8% | 22+109%88.9% | 11—76.2% | −1.3r9.3—−19.2% | −2.9r29−105%−8.3% | 59—93.8% | |
| Total liabilities and equity | 11+266%100% | 3.0−54.1%100% | 6.6−55.0%100% | 15−64.1%100% | 41+63.8%100% | 25+79.4%100% | 14+110%100% | 6.6r10−81.1%100% | 35−44.6%100% | 63—100% | |
| Shares outstanding | 0.5r0.0+454%— | 0.1r1.4−80.5%— | 0.5r3.9−78.2%— | 2.3+24.7%— | 1.8r45−92.4%— | 24+428%— | 4.5+122%— | 2.0r18−88.6%— | 18+6.1%— | 17—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.0+61.6%— | 0.0−56.0%— | 0.0+50.5%— | 0.0−65.2%— | 0.0+6.2%1.0% | 0.0−85.8%0.3% | 0.1+652%3.7% | 0.0—0.9% | — | — | |
| Share-based compensation | 0.2−20.0%— | 0.3−47.8%— | 0.5−34.1%— | 0.8+42.5%— | 0.6+75.0%30.4% | 0.3−57.5%6.1% | 0.8+2328%21.7% | 0.0r1.9−99.3%1.6% | 4.2−35.8%331% | 6.6—650% | |
| Cash from operating activities | −4.8—— | −4.5—— | −13—— | −18—— | −10—−554% | −10—−197% | −12−377%−334% | 4.2r−24—214% | −28—−2175% | −32r−32—−3171% | |
| Capital expenditure | −0.6—— | 0—— | — | — | 0—0.0% | −0.0—−0.0% | 0—0.0% | 0—0.0% | −0.1—−8.9% | −0.6—−55.3% | |
| Cash from investing activities | 0.8—— | 0—— | 0—— | −1.5—— | 0—0.0% | −0.0−100%−0.0% | 5.6—162% | 0r14−100%0.0% | 24—1922% | −12—−1211% | |
| Shares issued | — | — | — | — | — | — | — | 2.9—147% | — | — | |
| Dividends paid | — | — | — | — | — | 0—0.0% | −0.1—−3.9% | 0—0.0% | — | — | |
| Cash from financing activities | 12+1064%— | 1.1−84.0%— | 6.6+234%— | 2.0−93.0%— | 28+59.9%1538% | 18+394%338% | 3.6+149%103% | 1.4r0.1+54431%73.6% | 0.0−88.1%0.2% | 0.0—2.2% | |
| Change in cash | 8.3—— | −3.5—— | −6.2—— | −17−195%— | 18+145%983% | 7.4—141% | −2.4−143%−69.1% | 5.6r−9.4—288% | −3.2—−253% | −44—−4380% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 0.3—100% | 0.2—100% | — | — | 0—— | 0—— | — | — | — | — | — | — | |
| Research and development | 3.7+772%— | 1.6+2446%512% | 1.3+1021%573% | 0.7+893%— | 0.1*−34.7%— | 0.1−54.9%— | 0.1−45.7%— | 0.1−68.9%— | 0.2*+192%— | 0.1—— | 0.2—— | 0.2—— | 0.1*—— | |
| General and administrative | 5.0+8.0%— | 1.7+110%568% | 1.3+56.2%583% | 1.5−6.6%— | 0.4*−69.4%— | 0.8−4.1%— | 0.8−32.2%— | 1.6+7.5%— | 1.3*+44.2%— | 0.9—— | 1.3—— | 1.5—— | 0.9*—— | |
| Operating expenses | 17+241%— | 3.3+271%1080% | 2.6+172%1156% | 2.3+32.9%— | 9.0*+507%— | 0.9−11.1%— | 1.0−34.2%— | 1.7−3.0%— | 1.5*+53.4%— | 1.0—— | 1.5—— | 1.8—— | 1.0*—— | |
| Operating income | −17—— | −3.0—−980% | −2.6—−1156% | −2.3—— | −9.0*—— | −0.9—— | −1.0—— | −1.7—— | −1.5*—— | −1.0—— | −1.5—— | −1.8—— | −1.0*—— | |
| Income from continuing operations | — | — | — | −2.2—— | — | −0.9—— | −1.0—— | −1.7—— | — | −1.0—— | −1.4—— | −1.7—— | — | |
| Net income attributable to shareholders | −17—— | −3.0—−972% | −2.4—−1043% | −2.2—— | −9.0*—— | −0.9—— | −1.0—— | −1.7—— | −1.5*—— | −1.0—— | −1.4—— | −1.7—— | −0.9*—— | |
| Earnings per share, basic | — | -3.53—— | -4.46—— | -4.18—— | — | -21.76r-1.81—— | -81.21r-0.45—— | -240.07r-1.03—— | — | -11.38r-0.76—— | -2.37—— | -3.27r-0.41—— | — | |
| Earnings per share, diluted | — | -3.53—— | -4.46—— | -4.18—— | — | -21.76r-1.81—— | -81.21r-0.45—— | -240.07r-1.03—— | — | -11.38r-0.76—— | -2.37—— | -3.27r-0.41—— | — | |
| Shares, weighted average (basic) | 0.8+2007%— | 0.8+2007%— | 0.5+4410%— | 0.5+7370%— | — | 0.0r0.5−53.0%— | 0.0r2.1−98.0%— | 0.0r1.7−98.6%— | — | 0.1r1.3—— | 0.6—— | 0.5r4.2—— | — | |
| Shares, weighted average (diluted) | 0.8+2007%— | 0.8+2007%— | 0.5+4410%— | 0.5+7370%— | — | 0.0r0.5−53.0%— | 0.0r2.1−98.0%— | 0.0r1.7−98.6%— | — | 0.1r1.3—— | 0.6—— | 0.5r4.2—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 8.2—92.9% | 8.2+69.8%92.9% | 8.3+943%92.1% | 7.8+335%92.8% | 11+340%96.9% | 4.8+46.5%78.9% | 0.8−75.7%57.1% | 1.8−58.9%76.9% | 2.4−58.7%80.5% | 3.3—85.1% | 3.3—92.1% | 4.4—89.5% | 5.9—89.6% | |
| Other current assets | 0.2—2.4% | 0.2+158%2.4% | 0.1+452%1.6% | 0.3+396%3.6% | 0.3+530%2.5% | 0.1−32.0%1.3% | 0.0−82.5%1.9% | 0.1−65.4%2.6% | 0.0−71.1%1.4% | 0.1—3.1% | 0.2—4.3% | 0.2—3.6% | 0.2—2.3% | |
| Current assets | 8.4—95.3% | 8.4+38.2%95.3% | 8.6+531%95.2% | 8.4+263%99.2% | 11+268%99.4% | 6.1+58.7%99.5% | 1.4−61.3%97.6% | 2.3−52.3%98.5% | 3.0−54.2%98.8% | 3.8—99.1% | 3.5—98.9% | 4.8—98.9% | 6.5—99.0% | |
| Property, plant and equipment | 0.4—4.4% | 0.4—4.4% | 0.4—4.4% | 0.0—0.4% | 0.0—0.4% | — | — | — | 0—0.0% | — | — | — | — | |
| Total assets | 8.8—100% | 8.8+44.2%100% | 9.0+546%100% | 8.4+260%100% | 11+266%100% | 6.1+58.0%100% | 1.4−60.8%100% | 2.3−52.1%100% | 3.0−54.1%100% | 3.9—100% | 3.6—100% | 4.9—100% | 6.6—100% | |
| Accounts payable | 0.8—8.9% | 0.8−29.5%8.9% | 1.3−10.5%14.7% | 0.9−36.4%11.1% | 0.9+0.4%8.5% | 1.1+566%18.1% | 1.5+130%106% | 1.5+106%62.9% | 0.9+55.4%31.0% | 0.2—4.3% | 0.6—18.1% | 0.7—14.6% | 0.6—9.2% | |
| Current liabilities | 4.2—48.3% | 4.2—48.3% | 4.7—52.0% | 4.5—54.0% | 5.2+242%46.7% | — | — | — | 1.5—50.0% | — | — | — | — | |
| Total liabilities | 4.2—48.3% | 4.2+130%48.3% | 4.7+111%52.0% | 4.5+99.6%54.0% | 5.2+242%46.7% | 1.8+97.8%30.3% | 2.2+88.6%160% | 2.3+84.5%97.4% | 1.5+16.3%50.0% | 0.9—24.2% | 1.2—33.2% | 1.2—25.3% | 1.3—19.7% | |
| Retained earnings | −102—−1160% | −102—−1160% | −99—−1100% | −97—−1148% | −94—−854% | −85—−1402% | −85—−6074% | −84—−3575% | −82—−2710% | −80—−2085% | −79—−2237% | −78—−1598% | −76—−1159% | |
| Shareholders' equity | 4.5—51.7% | 4.5—51.7% | 4.3—48.0% | 3.9+6167%46.0% | 5.9+290%53.3% | −4.2r4.2−245%−69.7% | −0.8−135%−59.6% | 0.1−98.3%2.6% | 1.5−71.4%50.0% | 2.9—75.8% | 2.4—66.8% | 3.6—74.7% | 5.3—80.3% | |
| Total liabilities and equity | 8.8—100% | 8.8+44.2%100% | 9.0+546%100% | 8.4+260%100% | 11+266%100% | 6.1+58.0%100% | 1.4−60.8%100% | 2.3−52.1%100% | 3.0−54.1%100% | 3.9—100% | 3.6—100% | 4.9—100% | 6.6—100% | |
| Shares outstanding | 2.4—— | 2.4+153%— | 0.5−75.0%— | 0.5−74.4%— | 0.5r0.0+454%— | 0.9−34.5%— | 2.1+232%— | 2.1−51.7%— | 0.1r1.4−80.5%— | 1.4—— | 0.6—— | 4.3—— | 0.5r3.9—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.0+991%— | 0.0*+2148%8.1% | 0.0*+1133%6.0% | 0.0+436%— | 0.0*+247%— | 0.0*+0.1%— | 0.0*0.0%— | 0.0−0.1%— | 0.0*+0.1%— | 0.0*—— | 0.0*—— | 0.0—— | 0.0*—— | |
| Share-based compensation | 0.8+522%— | 0.3*+1009%82.4% | 0.2*+790%90.6% | 0.2+535%— | 0.1*+173%— | 0.0*−61.9%— | 0.0*−72.8%— | 0.0−56.7%— | 0.1*−40.2%— | 0.1*—— | 0.1*—— | 0.1—— | 0.1*—— | |
| Cash from operating activities | −9.3—— | −2.6*—−842% | −2.7*—−1165% | −2.9—— | −1.1*—— | −1.6*—— | −0.9*—— | −1.2—— | −0.7*—— | −1.4*—— | −1.1*—— | −1.4—— | −1.5*—— | |
| Cash from investing activities | — | −0.1*—−25.8% | — | — | 1.0*—— | −0.2*—— | — | — | 0*—— | — | — | — | 0*—— | |
| Cash from financing activities | 12+91.3%— | 2.5*−56.6%828% | 3.2*—1390% | 0−100%— | 6.1*—— | 5.9*+329%— | −0.1*—— | 0.5—— | −0.1*—— | 1.4*—— | −0.0*—— | −0.2—— | −0.2*—— | |
| Change in cash | 3.4+120%— | −0.1*−103%−39.4% | 0.5*—206% | −2.9—— | 5.9*—— | 4.0*+35727%— | −1.0*—— | −0.6—— | −0.8*—— | 0.0*—— | −1.1*—— | −1.5—— | −1.7*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Decoy Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 4 · Unregistered share sale 3 · Shareholder rights changed 3 · Bylaws or fiscal year changed 3 · Shareholder vote 5
| Filed | What happened | Filing |
|---|---|---|
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Material agreementShareholder rights changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 23, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 60% of workforce | Restructuring planSEC 8-K | “In connection with the restructuring plan, the Company plans to reduce its workforce by approximately 60%, with the majority of the reduction in personnel expected to be completed …” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Decoy Therapeutics Inc. compares in Biotechnology
- Market cap$2 M · higher than 2% of 726
- Revenue growth-64.8% · higher than 14% of 438
- Price / book0.4× · lower than 94% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Decoy Therapeutics Inc.🇺🇸 | $2 M | — | — | -64.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 23, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Decoy Therapeutics Inc.? Verify and update this profile — free
Show Decoy Therapeutics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.